Patents by Inventor Roland Valdes, Jr.
Roland Valdes, Jr. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9435814Abstract: The presently-disclosed subject matter provides methods and kits for diagnosing obstructive sleep apnea (OSA) in a subject, such as a human child, wherein a biological sample is provided from the subject and the amount of a Urocortin III peptide is determined from the sample. Further provided are methods for diagnosing OSA in a subject wherein the amount of a Urocortin III peptide and one or more peptides selected from a Uromodulin peptide, an Orosomucoid 1 peptide, and a Kallikrein 1 peptide are determined in a biological sample from a subject.Type: GrantFiled: March 6, 2015Date of Patent: September 6, 2016Assignee: UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC.Inventors: David Gozal, Saeed A. Jortani, Roland Valdes, Jr., Leila Kheirandish-Gozal
-
Publication number: 20160161489Abstract: The present invention provides a method of identifying and isolating a set of monoclonal and polyclonal antibodies for use in immunometric assays for the detection of UCN III peptide, and the development of a two-site immunoassay for UCN III peptide. Monoclonal antibodies (mAb) have been affinity purified and used to develop a two-site immunometric assay comprising a mAb selected from the list comprising 2F7, 4E3, 4D3, 6D1, 1G10, 2E7, 4F3, 4C3, 5E11, 1A9, 4C4, 4B4, 2G7, 2A4, 1B9, 3H11, 5F2, 4G2, and 2E3 used for capture and a polyclonal antibody used for detection. The immunometric assay of the present invention comprise a method to identify and isolate specific antibodies or fragments thereof establishing the presence and/or amount of a UCN III peptide and detecting the specific binding necessary for determining a sample's UCN III peptide level for correlation with a diagnosis wherein the UCN III peptide level is used to determine whether the subject suffers from OSA.Type: ApplicationFiled: September 15, 2015Publication date: June 9, 2016Inventors: Mark W. Linder, Kevin Goudy, Roland Valdes, JR.
-
Publication number: 20150177264Abstract: The presently-disclosed subject matter provides methods and kits for diagnosing obstructive sleep apnea (OSA) in a subject, such as a human child, wherein a biological sample is provided from the subject and the amount of a Urocortin III peptide is determined from the sample. Further provided are methods for diagnosing OSA in a subject wherein the amount of a Urocortin III peptide and one or more peptides selected from a Uromodulin peptide, an Orosomucoid 1 peptide, and a Kallikrein 1 peptide are determined in a biological sample from a subject.Type: ApplicationFiled: March 6, 2015Publication date: June 25, 2015Inventors: David Gozal, Saeed A. Jortani, Roland Valdes, JR., Leila Kheirandish-Gozal
-
Patent number: 8999658Abstract: The presently-disclosed subject matter provides methods and kits for diagnosing obstructive sleep apnea (OSA) in a subject, such as a human child, wherein a biological sample is provided from the subject and the amount of a Urocortin III peptide is determined from the sample. Further provided are methods for diagnosing OSA in a subject wherein the amount of a Urocortin III peptide and one or more peptides selected from a Uromodulin peptide, an Orosomucoid 1 peptide, and a Kallikrein 1 peptide are determined in a biological sample from a subject.Type: GrantFiled: September 25, 2009Date of Patent: April 7, 2015Assignee: University of Louisville Research Foundation, Inc.Inventors: David Gozal, Saeed A. Jortani, Roland Valdes, Jr., Leila Kheirandish-Gozal
-
Patent number: 8380539Abstract: The invention provides personalized medicine management software for determining a series of recommended doses of a medication for a patient. The software contains code to receive information regarding a combination of at least one genetic factor and personal attributes for the patient that are predictive of the patient's reaction to a series of doses of the medication. Using a predictive mathematical model specific to the medication, the code calculates the series of recommended doses specific to the patient's genetic factor and personal attributes and specific to the medication. The series of recommended doses is outputted. In preferred embodiments, the output is the form of an interactive display. The interactive display permits a user, typically a health care professional, to input actual doses and actual patient responses. The subsequent series of recommended doses is preferably then adjusted, in real time, to account for the actual doses and actual patient responses.Type: GrantFiled: May 8, 2007Date of Patent: February 19, 2013Assignee: University of Louisville Research Foundation, Inc.Inventors: Mark W. Linder, Roland Valdes, Jr.
-
Publication number: 20110319351Abstract: The invention provides methods to treat cancer with cardiac glycosides.Type: ApplicationFiled: May 10, 2011Publication date: December 29, 2011Applicant: University of Louisville Research FoundationInventors: Roland Valdes, JR., Kenneth Ihenetu, Rafael Fernandes-Botran, Hassan Qazzaz
-
Publication number: 20110217719Abstract: The presently-disclosed subject matter provides methods and kits for diagnosing obstructive sleep apnea (OSA) in a subject, such as a human child, wherein a biological sample is provided from the subject and the amount of a Urocortin III peptide is determined from the sample. Further provided are methods for diagnosing OSA in a subject wherein the amount of a Urocortin III peptide and one or more peptides selected from a Uromodulin peptide, an Orosomucoid 1 peptide, and a Kallikrein 1 peptide are determined in a biological sample from a subject.Type: ApplicationFiled: September 25, 2009Publication date: September 8, 2011Applicant: UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC.Inventors: David Gozal, Saeed A. Jortani, Roland Valdes, JR., Leila Kheirandish-Gozal
-
Publication number: 20090138286Abstract: The invention provides personalized medicine management software for determining a series of recommended doses of a medication for a patient. The software contains code to receive information regarding a combination of at least one genetic factor and personal attributes for the patient that are predictive of the patient's reaction to a series of doses of the medication. Using a predictive mathematical model specific to the medication, the code calculates the series of recommended doses specific to the patient's genetic factor and personal attributes and specific to the medication. The series of recommended doses is outputted. In preferred embodiments, the output is the form of an interactive display. The interactive display permits a user, typically a health care professional, to input actual doses and actual patient responses. The subsequent series of recommended doses is preferably then adjusted, in real time, to account for the actual doses and actual patient responses.Type: ApplicationFiled: May 8, 2007Publication date: May 28, 2009Inventors: Mark W. Linder, Roland Valdes, Jr.
-
Publication number: 20090018088Abstract: The invention provides methods to treat cancer with cardiac glycosides.Type: ApplicationFiled: June 2, 2008Publication date: January 15, 2009Applicant: University of Louisville Research FoundationInventors: Roland Valdes, JR., Kenneth Ihenetu, Rafael Fernandes-Botran, Hassan Qazzaz
-
Patent number: 6835715Abstract: A novel mammalian dihydroouabain-like factor is disclosed which substantially fails to cross-react with mammalian ouabain-like factor (OLF) for binding to anti-OLF antibody, but cross-reacts with plant-related dihydroouabain (dho) for binding to anti-dho antibody, has maximal u.v. absorbance at 196 nm, has a non-peptidic, non-lipidic chemical structure and a fully hydrogenated lactone ring, has a concentration-dependent Na+,K+-ATPase (sodium pump) catalytic inhibitory activity which is 10-fold lower than OLF and 3-fold higher than plant-related dihydroouabain, and a high pressure liquid chromatography elution time about the same as dho. This factor is useful for therapy for congestive heart failure. An antibody and antibody fragments having affinity for mammalian Dh-OLF but not for OLF, and diagnostic and therapeutic methods comprise the antibody and means for quantifying the antibody and are useful for treating a condition caused by high level of OLF or Dh-OLF.Type: GrantFiled: February 11, 2000Date of Patent: December 28, 2004Assignee: University of Louisville Research Foundation, Inc.Inventors: Roland Valdes, Jr., Hassan M. A. M. Qazzaz